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A B S T R A C T
Schizophrenia is a heterogeneous disorder characterized by a spectrum of symptoms and many different un-
derlying causes. Thus, instead of using the broad diagnosis, intermediate phenotypes can be used to possibly
decrease the underlying complexity of the disorder. Alongside the classical symptoms of delusions and hallu-
cinations, cognitive deficits are a core feature of schizophrenia. To increase our understanding of the biological
processes related to these cognitive deficits, we performed a genome-wide gene expression analysis. A battery of
14 neuropsychological tests was administered to 844 individuals from a Finnish familial schizophrenia cohort.
We grouped the applied neuropsychological tests into five factors for further analysis. Cognitive en-
dophenotypes, whole blood mRNA, genotype, and medication use data were studied from 47 individuals.
Expression level of several RNA probes were significantly associated with cognitive performance. The factor
representing Verbal Working Memory was associated with altered expression levels of 11 probes, of which one
probe was also associated with a specific sub-measure of this factor (WMS-R Digit span backward). While, the
factor Processing speed was related to one probe, which additionally associated among 55 probes with a specific
sub-measure of this factor (WAIS-R Digit symbol). Two probes were associated with the measure recognition
memory performance. Enrichment analysis of these differentially expressed probes highlighted immunological
processes. Our findings are in line with genome-wide genetic discoveries made in schizophrenia, suggesting that
immunological processes may be of biological interest for future drug design towards schizophrenia and the
cognitive dysfunctions that underlie it.
1. Introduction
Schizophrenia is a heterogeneous mental disorder characterized by
a spectrum of psychological symptoms. In addition to positive and ne-
gative symptoms, cognitive deficits are a core feature of the illness
(American Psychiatric Association, 1994). Several domains of
cognition, including attention (Cornblatt and Erlenmeyer-Kimling,
1985), verbal skills, working memory, learning, and processing speed
(McGrath et al., 2014; Dickinson et al., 2004; Nuechterlein et al., 2004)
are impaired in individuals with schizophrenia. These impairments can
vary from mild to severe between patients, however, within the same
patient, cognitive dysfunctions are fairly stable over time. Impairments
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in cognitive functions are often present already before the hallmark
positive symptoms of the illness appear (Cornblatt and Erlenmeyer-
Kimling, 1985). Antipsychotic medications, commonly prescribed to
treat schizophrenia, do not provide clinically meaningful improvements
on the patients' cognitive domains (Koola et al., 2014). This means that
treatment of the cognitive dysfunctions in people with schizophrenia is
one of the great unmet clinical challenges (Keefe et al., 2013; Koola
et al., 2014).
Intermediate endophenotypes have been proposed to facilitate un-
covering the heterogeneous genetic aetiology of schizophrenia.
Endophenotypes are invisible but measurable illness-related traits,
which are assumed to be closer to a neurobiological aetiology than the
disorder itself or its' varying symptoms (Flint and Munafo, 2007;
Gottesman and Gould, 2003; Gottesman and Shields, 1973). Key qua-
lities of an endophenotype are heritability, state independency, and the
fact that they might be manifested in unaffected relatives of a patient
(Gottesman and Gould, 2003). The aforementioned characteristics have
been suggested to make endophenotypes ideal alternative measures in
the study of the biological aetiology of familial complex traits. Cogni-
tive ability fulfils these characteristics of an endophenotype, it is in-
herited, and unaffected family members of a patient may show mild
deficits (e.g. Braff, 2015). Many cognitive variables, such as, measures
of verbal learning, working memory, and attention, have been sug-
gested to function as schizophrenia related endophenotypes (Flint and
Munafo, 2007; Tuulio-Henriksson et al., 2003; Tuulio-Henriksson et al.,
2002).
Through the application of endophenotypes in genetic analysis,
several genetic loci have previously been associated with cognitive
functioning in schizophrenia. Family-based studies have linked the
chromosome regions 1q (Cannon et al., 2005; Hennah et al., 2005), 2q
(Paunio et al., 2004), 4q (Paunio et al., 2004), and 7q22 (Wedenoja
et al., 2008; Wedenoja et al., 2010), containing the DISC1, TSNAX, and
RELN genes in Finnish families. Population-based studies have asso-
ciated the genomic regions nearby or in the genes ATRNL1, KRTAP7-1,
C9orf5, CRTC3, MYRIP, DCDC2, FAM110C, DIP2C, KCTD2 (Luciano
et al., 2011), CADM2 (Ibrahim-Verbaas et al., 2016), TCF20, CACNA1C,
and AKAP6 (Smeland et al., 2017). Here, as in those for schizophrenia,
observations from population-based studies are markedly different to
those made in familial studies, highlighting the issue of heterogeneity
also in this genetic aetiology. To date, genome-wide studies specifically
of intelligence, that is often described as combination of many cognitive
abilities, have identified a total of 18 independent genomic loci and 22
genes (Sniekers et al., 2017).
In the case of gene expression analysis with endophenotypes, a
previous study within Swedish and Finnish twin cohorts studied the
genome-wide expression levels of genes, identifying under-expression
of genes in relation to memory performance in schizophrenia patients
(Zheutlin et al., 2016). The memory related probes associated in this
study with diagnostic status and verbal memory as an endophenotype
were overlapping with genes that have been previously associated with
schizophrenia (SMARCAL1, MCM3, SBK1, ZNF142, ATIC, CBLB, ELP3,
ACO1, GTPBP3, YARS, and RUNX3), as well as neurocognition (NCALD)
(Zheutlin et al., 2016).
Thus, we set out to investigate if genome-wide gene expression
variables can be identified to associate with psychological en-
dophenotypes in familial schizophrenia, and therefore highlight any
biological processes that may be disrupted in these traits. In order to
increase our understanding of the biological aetiology of cognitive
dysfunction in schizophrenia. Such an approach has the potential to
further our understanding of the pathophysiology of this devastating
disorder, and identify prospective mechanisms through which it may be
possible to design future treatments.
2. Material and methods
2.1. Study samples
The samples used here are part of a larger study project of familial
schizophrenia: Genetic Epidemiology and Molecular Genetics of
Schizophrenia in Finland. In these projects, individuals born between
the years 1940 and 1976 with a diagnosis of schizophrenia, schi-
zoaffective disorder or schizophreniform disorder were identified from
three nationwide health care registers: the Finnish Hospital Discharge
Register, the Pension Register and the Medication Reimbursement
Register (Hennah et al., 2003; Hovatta et al., 1998). Two samples with
high familial loading for schizophrenia were collected. The first sample
consisted of families with schizophrenia, schizoaffective disorder or
schizophreniform disorder collected from a Finnish sub-isolate with an
increased relative- risk (Hovatta et al., 1997) for schizophrenia. The
other sample was collected from the rest of Finland and consisted of
families with at least two siblings with schizophrenia, schizoaffective
disorder or schizophreniform disorder. The Diagnostic and Statistical
Manual of Mental Disorders, fourth edition, (DSM-IV) (American
Psychiatric Association, 1994) diagnoses were made from affected fa-
mily members by a mental health professional at psychiatric hospitals
and outpatient care centres (Arajärvi et al., 2004). Based on these di-
agnoses two researchers independently made best estimate consensus
diagnoses using the DSM-IV criteria (American Psychiatric Association,
1994). If there was a disagreement, a third researcher reviewed the case
to achieve the diagnoses (Arajärvi et al., 2004).
Here, we utilized the neuropsychological measurements attained
from both schizophrenia patients and their unaffected family members.
For some participated families, this test battery had been applied
alongside a collection of mRNA and DNA, and performed at two time-
points. The first neuropsychological measurements were performed
between the years 1998 and 2002 (first time-point), and the second
neuropsychological measurements were performed between the years
2006 and 2008 (second time-point). The first time-point data consisted
of 844 individuals from 274 families, and the second time-point 52
individuals from 15 families. Of these, 21 individuals had participated
in both data collections (an average of 5 years between measurements).
A total of 31 individuals from 10 families participated only in the
second time-point collection (Fig. S1 and Table S1).
Genome wide gene-expression data was produced from the mRNA
samples collected from the second time-point participants. This second
time-point collection had been based upon our prior genetic observa-
tions in those families. These include genetic association evidence at the
DISC1 (Hennah et al., 2003), NDE1 (Hennah et al., 2007), TOP3B (Stoll
et al., 2013) and RELN (Wedenoja et al., 2008) loci that have been
reported previously. Of these variants, the DISC1, NDE1 (Bradshaw
et al., 2017), and TOP3B (Stoll et al., 2013) loci have previously been
studied for altering gene-expression in this cohort. However, DISC1 did
not significantly affect gene-expression (Bradshaw et al., 2017), the
TOP3B deletion only significantly affects the expression level of the
TOP3B gene (Stoll et al., 2013), whereas the NDE1 variants are reported
to significantly alter the expression levels of a large number of genes,
due to the presence of the micro RNA miR-484 being encoded at the
NDE1 locus (Bradshaw et al., 2017). Thus, the NDE1 variant rs2242549
was used as a covariate in this study. A medical condition, diagnosed by
a clinical expert, that was affecting cognition (head injury, N=1 and
dementia, N= 1) or missing all neuropsychological test scores
(N=12), were exclusion criteria for the gene expression analyses. In
total, neuropsychological measurements, genetic, and gene-expression
data was available from 47 individuals (15 families) (Table S1). Of the
gene-expression study participants (second time-point), 76.6% origi-
nated from the Finnish sub-isolate and 23.4% from the rest of Finland.
The study has been approved by the Coordinating Ethics committee
of the Hospital District of Helsinki and Uusimaa, and informed consent
was obtained from all participants.
L. Ukkola-Vuoti et al. Progress in Neuropsychopharmacology & Biological Psychiatry 88 (2019) 159–167
160
2.2. Phenotypes
The participants of this study underwent a large neuropsychological
assessment including a series of well-validated, and internationally used
instruments to measure cognitive ability. For details of the neu-
ropsychological data collection see Tuulio-Henriksson et al., (2002).
From the test battery, a total of 14 quantitative neuropsychological
measures were chosen for this study, based on the following criteria: 1.
The resulting variable was quantitative, 2. The variable was not
missing> 20% of its' data, and 3. Previous evidence of potential use as
a neuropsychological endophenotype was available. From the first
time-point (N=865), neuropsychological data together with genetic
data has been previously reported (Cannon et al., 2005; Hennah et al.,
2005; Paunio et al., 2004; Tuulio-Henriksson et al., 2002; Tuulio-
Henriksson et al., 2003; Wedenoja et al., 2008; Wedenoja et al., 2010),
demonstrating that several of our measures meet the criteria for en-
dophenotypes (Gottesman and Gould, 2003), and that these en-
dophenotypes have been useful in decreasing the underlying com-
plexity of the phenotype in genetic studies of familial schizophrenia in
Finland. The cognitive endophenotype measures used in the present
study were: Immediate recall, Short delay recall, Long delay recall, and
Recognition memory from the California Learning Test (CVLT) battery
(Delis et al., 1987); Digit Symbol, Block design, Similarities, and Vo-
cabulary from the Wechsler Adult Intelligence Scale–Revised (WAIS-R)
battery (Wechsler, 1981); Visual span forward and backward, and Digit
span forward and backward Wechsler Memory Scale-Revised
(Wechsler, 1987) battery; Stroop interference (Golden, 1978), and Trail
Making part A (Reitan, 1985). Trail Making part B was not used because
many patients had not managed to complete the task and therefore the
finishing time was missing.
Of the 14 variables, three (Recognition memory, Trail making part-
A, and Stroop interference) did not follow a normal distribution. These
three variables were transformed using Blom's normal score ranking
formula with IBM SPSS Statistics version 22.0.0.1 Only these normal-
ised values were used for further analysis.
Missing cognitive measures in this study were imputed because: 1)
constructing factors required full variable information, and 2) to pre-
vent reducing the second time-point sample size of the endophenotype
analyses by a minimum of two (4%: WMS-R Digit span forward and
WMS-R Visual span backward) to a maximum of nine (19%: Stroop
interference) study participants. For imputations both first and second
time-point measurements were combined (N=917), in order to in-
crease the amount of information available from which the imputations
can be made, and thus make them more precise. Of these individuals,
356 (38.8%) were diagnosed with schizophrenia spectrum disorder,
477 were males (52%) and the mean age was 49.68 years (range from
22.7 to 88.4 years). Before imputations the test scores of all variables
were transformed to the same order of magnitude. Here they were di-
vided either by 10 (Visual span forward, Visual span backward, Digit
span forward, Digit span backward, Long delay and Short delay) or by
100 (Immediate recall, Stroop interference, Trail making part A, Digit
symbol, Block design, Similarities, and Vocabulary) so that they all
were at the same scale as the Recognition memory test scores (The
mean of recognition memory test= 0.90). Imputations were performed
with IBM SPSS Statistics version 22.0.0.1 using multiple imputation
method (MCMC). Time-point, gender, diagnostic status within the
broad schizophrenia spectrum of disorders (American Psychiatric
Association, 1994), age at measurement and family were used as pre-
dictors for imputations. For each variable, the mean value from 10
imputations with 10,000 iterations was calculated and used for further
analyses. After imputation, the scores were transformed back to their
original scales.
The cognitive measures were hypothesised to group together based
on existing theory of the measured cognitive domains, so that the
measures from the same cognitive domain were grouped together (ex-
pected to correlate with each other). We conducted a confirmatory
factor analysis to examine the fit of this hypothesised latent factor
structure using the 14 normally distributed cognitive endophenotypes
from the first time-point data (N=865), that was not containing any
duplicate measurements from the same individual. After grouping, a
five-factor, and an alternative three-factor, model was explored (Table
S2). For this analysis, gender, diagnostic status of schizophrenia spec-
trum disorder and age at measurement were used as covariates, and
family affects as a random factor. As the cognitive endophenotype
measurements of this study had very different metrics, they all were
zero centered and transformed to be on the same scale. These
Standardised residuals from general linear regression model were used
for the factor analysis, and IBM SPSS Statistics version 22.0.0.1 was
used for creating the adjusted variables. Factor analysis was conducted
with the graphical interface Ωnyx (version 1.0–937) for creating and
estimating structural equation models (SEM) utilizing maximum like-
lihood estimation procedures (von Oertzen et al., 2015).
In addition to cognitive measures, medication use was explored as a
variable which could potentially effect gene-expression levels.
Medication data used in this study has been obtained from self-reported
data that was collected at the second-time point assessment at the same
time as the RNA sample was drawn. Previous studies have shown high
concordance between self-reported and official prescription database or
pharmacy records for antipsychotic (Haukka et al., 2007), cardiovas-
cular and hypertensive (Drieling et al., 2016) drug use. However, this
data means we know neither the dose being taken, nor whether the
medication is actually being taken. Here, all but two affected in-
dividuals self-reported as taking antipsychotic medication in general.
This meant we were not able to fully differentiate any effect of anti-
psychotic medications on gene expression from disorder status, which
was already being used as a covariate. Thus, we broke down the anti-
psychotic medication group into typical, atypical (excluding clozapine)
and clozapine, in order to see if there is any residual effect of these
more specific groupings. In addition, we used medication groupings for
antidepressant, anticholinergic, benzodiazepines and sedative-hypno-
tics, mood stabilizers (excluding lithium), lithium, statin, diabetes
medication, and antihypertensives and medication for ischemic heart
disease (for chemicals included in each group see Table S4).
2.3. Genotyping
The procedure used to genotype the NDE1 rs2242549 SNP has been
reported in our previous studies (Hennah et al., 2007; Tomppo et al.,
2009). Briefly, DNA was extracted from blood samples and genotyping
of the NDE1 rs2242549 SNP was performed using the Sequenom plat-
form (Sequenom Inc., San Diego, CA, US) according to the manufac-
turer's recommendations (Jurinke et al., 2001). The minor allele fre-
quency (MAF) of the NDE1 rs2242549 SNP (specifically the C allele)
that was added as a covariate into our analyses was 43.33% in the 1st
time-point and 43.62% in the 2nd time-point data (1000 Genomes: All
populations MAF=46.79%; Finnish from Finland MAF=49.49%).
2.4. Gene expression profiling
RNA was extracted from whole blood samples collected into
PAXgene tubes. The samples with RNA Integrity Number (RIN)>8
were used for further analyses. Genome-wide gene expression measures
were assayed using Illumina HumanHT-12 v4.0 Expression BeadChip
(Illumina Inc., San Diego, California, USA). Of the 48,212 probes on the
chip, 11,976 were significantly detectable at a threshold of p≤ .01
in> 90% of individuals. The expression data for these probes were
processed using quantile normalization followed by log2 transforma-
tion. Raw anonymous data regarding this family cohort can be accessed
at the Gene Expression Omnibus (GEO) database (GSE48072).
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2.5. Statistical analyses
Association between genome-wide expression levels and cognitive
endophenotypes, in the second time-point data (N=47), was calcu-
lated using linear regression model of standardised measures, and in-
cluded gender, age at measurement, affection status, family, and NDE1
rs2242549 genotype as covariates for the gene-expression values. We
applied the false discovery rate (FDR) of q≤ 0.05 to our discovery
observations (Storey, 2003). No multiple test correction has been made
to account for the 14 endophenotypes and five factors tested. Such a
correction would be overly conservative given that these en-
dophenotypes and factors are directly related. Thus, to further lower
the risk of type I error of a finding, we report if there is any supportive
evidence for that probe in analysis of related endophenotypes. The
analysis was performed with R (RStudio version 1.0.136) using qvalue
package (Storey, 2003). The post hoc power of our sample to detect
gene expression changes was estimated using ssize.fdr (Liu and Hwang,
2007). While this was verified to be sufficient (Fig. S2), this power is
expected to be reduced when using multivariate analysis with three
covariates as performed here.
Effect of medication on gene-expression measures was explored by
fitting a linear regression model for each medication group and each
probe using R (RStudio version 1.0.136).
The findings from microarray analysis were further studied to
evaluate any enrichment within specific biological functions of the
genes that were associated with the cognitive measures. The analysis
was performed with Qiagen's Ingenuity Pathway Analysis software
(IPA) (www.ingenuity.com/index.html). To allow more probes to move
forward to enrichment analysis, we used a more permissive FDR q-value
≤ 0.10.
3. Results
Descriptive statistics of the cognitive measures used in this study are
shown in Table 1. The 15 families in which the participants belonged
included from 1 to 9 individuals each, of which from 1 to 3 were di-
agnosed with a disorder on the schizophrenia spectrum. In total, 38.3%
of the second time-point individuals were diagnosed with schizo-
phrenia. At the second time-point (when the RNA-sample and the en-
dophenotype measurements were taken), the mean age of the
participants was 55 years (range from 40.07 to 84.71).
3.1. Factor analysis
The hypothesised five-factor model, in which the same cognitive
domains and test batteries were grouped together, explored with con-
firmatory factor analysis (CFA) provided an excellent fit for all 14
cognitive measures. The goodness-of-fit statistics for the best model
were: Root Mean Square Error of Approximation (RMSEA) 0.049 (90%
CI 0.048 to 0.063) (RMSEA<0.05 model of good fit), Comparative Fit
Index (CFI) 0.970 (CFI cut-off>0.95), Trucker Lewis Index (TLI) 0.954
(TLI cut-off>0.95), and x2(66)= 241.16 (p < .0001). Covariation
between the factors ranged from 0.46 to 0.74. In the five-factor model,
Block design was the only variable that was not showing> 0.40
loading to factors, that is considered as a cut-off for loading. Though,
the five-factor model in which this cross–loading on latent factor verbal
skills was removed, showed lower model fitting statistics
(RMSEA=0.046; CFI= 0.97; TLI= 0.945; x2(66)= 213.44). Here
Block design loaded to factors representing both Processing speed and
Verbal skills, which may arise from the fact that Block design usually
correlates with a broad range of cognitive tasks including processing
speed and verbal intelligence (Cockcroft et al., 2015). In general, Block
design loads onto the factor representing either visual ability or rea-
soning (Nuechterlein et al., 2004). As Block design was the only mea-
sure in our test battery that would contribute to generation of a visual
ability and/or reasoning factor, such a factor was not generated here.
The five-factor model with variables that are loading on each of them
are shown in Fig. 1. An alternative three-factor model had lower
goodness-of-fit statistics RMSEA=0.061; CFI= 0.95; TLI= 0.918;
x2(66)= 354.42) (Table S2), further suggesting our five-factor model is
the best fit.
The factor scores, that were used for further analyses with gene
expression data, were calculated for each factor by multiplying each
response by the respective regression weight obtained from CFA and the
products were summed, for example the factor Verbal learning and
memory= (Long delay recall * 0.92)+ (Short delay recall *
0.9)+ (Immediate recall * 0.87)+ (Recognition memory * 0.67).
Table 1
Descriptive statistics of cognitive variables⁎ from the factorization and the gene-expression data (1st and 2nd time-points), and the number of probes associated with
cognitive endophenotypes at the FDR threshold q≤0.05 and q≤0.10. Missing data describes the amount of data missing before the imputations were conducted for
the endophenotypes. CVLT=California Learning Test, WAIS-R=Wechsler Adult Intelligence Scale—Revised, and WMS-R=Wechsler Memory Scale—Revised.
Factor Test battery Variable Range 1st and 2nd time-point, N=844 2nd time-point, N= 47 N of significant probes
Missing (N) Non imputed mean Imputed mean SD Imputed mean SD q ≤0.05 q≤0.1
Verbal learning & memory 0 0
CVLT Long delay recall 0–16 2.1% (19) 9.24 9.20 3.61 8.38 3.76 0 0
CVLT Short delay recall 0–16 2.2% (20) 8.75 8.71 3.54 7.45 3.44 0 0
CVLT Immediate recall 0–80 1.7% (16) 42.02 41.88 13.61 37.00 15.11 0 0
CVLT Recognition memory 0.36–1.0 2.1% (19) 0.90 0.90 0.10 0.84 0.21 2 2
Processing speed 0 1
STROOP Stroop interference 7.8–378 18.4% (169) 85.20 88.84 38.12 103.23 49.02 0 0
TRAIL Trail making part A 15–320 14.6% (134) 55.58 57.97 31.61 47.18 21.81 0 0
WAIS-R Digit symbol 0–93 3.1% (28) 35.78 35.24 15.13 38.44 14.31 9 55
WAIS-R Block design 0–51 6.1% (56) 24.30 23.74 11.15 25.01 12.75 0 0
Verbal skills 0 0
WAIS-R Similarities 0–34 1.6% (15) 22.44 22.38 6.08 22.59 6.61 0 0
WAIS-R Vocabulary 0–70 1.9% (17) 38.06 37.86 13.55 36.25 13.69 0 0
Visual working memory 0 0
WMS-R Visual span forward 0–14 1.1% (10) 7.86 7.85 1.85 7.88 1.47 0 0
WMS-R Visual span backward 0–14 0.9% (8) 7.05 7.04 2.23 6.83 2.12 0 0
Verbal working memory 10 11
WMS-R Digit span backward 0–14 0.7% (6) 6.31 6.31 1.93 6.11 2.04 1 1
WMS-R Digit span forward 0–14 0.8% (7) 5.44 5.44 0.11 5.30 1.92 0 0
⁎ Values shown are based on the raw scores of the variables. Scores have been both normalised and standardised for analysis.
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3.2. Genome-wide gene expression and cognitive performance
Of the 11,976 studied probes, expression levels of 10 probes were
associated at the FDR q < 0.05 level with the factor representing
Verbal working memory, and an additional 1 probe at the FDR q < 0.1
level. One probe was related to the factor Processing speed at the FDR
q < 0.1 level. Of the cognitive measures from which the factors were
constructed, 9 probes were associated at the FDR q < 0.05 level with
WAIS-R Digit symbol (46 probes additionally associated at the FDR
q < 0.1 level), 2 probes with CVLT Recognition memory, and 1 with
WMS-R Digit Span backward. The probe for RTN4 gene was associated
with both the factor Processing speed and its' sub-measure WAIS-R Digit
symbol (q < 0.1). While, the probe for FAM89A was related to both
factor Verbal working memory and its' measure WMS-R Digit Span
backward (q < 0.1). The strongest association in our study was pro-
vided by the probe for the HYDIN gene with recognition memory
(q= 0.016). The number of probes exceeding significance level
q < 0.05, and suggestive significance level q < 0.1 are shown in
Table 1 and in more detail in Supplementary Table S3 and Fig. S3.
3.3. Biological pathways in which detected genes were enriched
Identification of the top canonical pathways and biological func-
tions were performed with Ingenuity Pathway Analysis (IPA) for the
factor Verbal working memory, and the specific measure WAIS-R Digit
symbol (Table 2) containing 11 and 55 probes, respectively. Pathway
analysis showed that the genes associated with cognitive en-
dophenotypes are enriched for functions in immune or inflammatory
mechanisms, including EIF2 signalling, and Antigen presentation, as
well as in molecular and cellular functions related to cell death and
survival, including DNA double-strand break repair by homologous
recombination, and DNA double-strand break repair by non-homo-
logous end joining.
3.4. Medication effect
A total of 38 different medications belonging to 11 medication
groups (splitting antipsychotics into typical, atypical excluding cloza-
pine, and clozapine) were explored (Supplementary Table S5). None of
Fig. 1. Five-factor model was obtained from confirmatory factor analysis (factors with grey color).
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the probes studied with respect to the medication groups survived false
discovery rate correction. However, IPA analysis of 66 probes asso-
ciated with clozapine use at an uncorrected significance level of
p < .01 demonstrated that they point towards similar immune related
biological pathways to those observed here with cognitive en-
dophenotypes. Canonical pathways enriched for clozapine use are
shown in Table S6.
4. Discussion
To date, the underlying deficits of human cognitive dysfunction are
unknown. In this study we found that gene expression measures can be
associated with cognitive endophenotypes for schizophrenia, and thus
highlight the biological processes that may be disrupted in these traits.
Here, expression levels of 55 RNA probes varied with the WAIS-R Digit
symbol, and11 RNA probes with the factor Verbal working memory.
One of the probes associated with the WAIS-R Digit symbol was for
the RTN4 gene (Reticulon 4; also known as NOGO) (q=0.03) encoding
Nogo protein (isoforms Nogo A, B, and C). In addition to this, RTN4 was
associated with the factor Processing speed (q < 0.1) in which the
aforementioned sub-measure belonged in, and tentatively (at the level
of uncorrected p < .05) with the three other sub-measures of this
factor (Stroop interference, Trail making part A, and WAIS-R Block
design). Here, lower cognitive performance correlated with lower RTN4
expression levels. Previously Nogo has been shown to have roles in
several developmental and adult synaptic plasticity related processes in
the brain, including cell migration, axon guidance, and myelination
(Schmandke et al., 2014), and functions including memory and motor
learning (Smedfors et al., 2018). In relation to the latter process, Nogo
has been demonstrated to be involved in autoimmune-mediated de-
myelination, a failure of the axons to regenerate after neurodegenera-
tive disorders or injury (Karnezis et al., 2004). Myelin dysfunction has
been suggested to be involved in pathogenesis of schizophrenia (Hakak
et al., 2001), and a previous study has shown decreased serum ex-
pression levels of Nogo in schizophrenia patients (Demirel et al., 2017).
In addition to schizophrenia, disturbed Nogo-signalling has been asso-
ciated with other psychiatric and neurological diseases, and activity of
the related genes has been shown to change from birth to old age
(Smedfors et al., 2018). Within the probes associated with the factor
Verbal working memory, one was representing the PTGER4 gene
(prostagladin E receptor 4) (q= 0.04). In addition, PTGER4 was ten-
tatively associated (at the level of uncorrected p < .001) with all sub-
measures of the factor (WMS-R Digit span backward, and WMS-R Digit
span forward). Here, lower cognitive performance correlated with
higher PTGER4 expression levels. Contrary to our observations, a pre-
vious study noted that the expression levels of immune-modulatory
genes, including PTGER4, were downregulated in the brains of schi-
zophrenia patients when compared to controls (Schmitt et al., 2011).
Lastly, a probe representing the hydrocephalus inducing gene HYDIN
was associated with the sub-measure assessing recognition memory
performance (q=0.02). In addition to this measure, this probe was
tentatively associated (at the level of uncorrected p < .0005) for other
sub-measures of the factor Verbal learning and memory (Immediate,
Short delay, and Long delay recall) and the factor itself (comprising of
measures Recognition memory, Immediate, Short delay, and Long delay
recall). Lower cognitive performance was related to lower HYDIN ex-
pression levels. In previous studies, deletions and duplications of the
HYDIN gene location has been associated with abnormal head size
(microcephaly or macrocephaly), and can manifest with develop-
mental, congenital, and behavioural abnormalities (Brunetti-Pierri
et al., 2008).
When the genes varying with cognitive performance were explored
together, enrichment within immune processes, and protein synthesis
control was detected (Table 2). Similarly, a previous study exploring
cognitive performance and gene expression levels showed enrichment
of genes related to immunology, RNA processing, and DNA replication
(Zheutlin et al., 2016). Specifically, they identified six genes related to
T and B cell signalling pathways (Zheutlin et al., 2016), which have
important roles also in the antigen presentation pathway. This previous
study used the CVLT performance as an endophenotype, while in our
study the observations of changes in expression level of genes related to
the antigen presentation pathway were correlated with the Digit symbol
test, and not those measures used here from the CVLT. Furthermore,
immune pathways, including antigen processing and presentation,
genes (MCH-region, e.g. HLA-G gene) showed enrichment in a study of
schizophrenia patients with cognitive impairment (Wu et al., 2016).
Thus there is a growing body of evidence suggesting that the aetiology
of schizophrenia may involve infectious or autoimmune processes from
epidemiological (Feigenson et al., 2014), genome-wide loci
(Schizophrenia Working Group of the Psychiatric Genomics, 2014),
genetic and proteomic (Chan et al., 2017), and gene expression
(Gardiner et al., 2013; Schmitt et al., 2011; Wu et al., 2016; Xu et al.,
2012) approaches.
Several cognitive endophenotypes, including general intelligence,
information processing speed, and memory, has been used to study
cognitive performance in schizophrenia (Hubbard et al., 2016), and in
healthy individuals (Ibrahim-Verbaas et al., 2016; Luciano et al., 2011;
Sniekers et al., 2017). The genetic background between cognitive
functioning and psychiatric diseases has been demonstrated to be
shared. A recent meta-analysis of genome-wide studies for intelligence
implicated association of 22 genes with intelligence, of which seven
have previously been shown to be associated to schizophrenia
(CYP2D6, NAGA, NDUFA6, TCF20, SEPT3, FAM109B and MEF2C)
(Sniekers et al., 2017). Furthermore, a schizophrenia polygenetic risk
score was associated with lower performance intelligence, and in the
reciprocal analysis a polygenetic risk score for performance intelligence
associated with increased risk for schizophrenia, although the genetic
overlap with full intelligence was weaker (Hubbard et al., 2016).
Epidemiological studies suggest that familial history of schizo-
phrenia is the strongest single indicator of individual schizophrenia risk
(Mortensen et al., 2010). There is consistent evidence of correlation
between family history of schizophrenia and a slight reduction in a
Table 2
Biological pathways in which genes associated with cognitive endophenotypes were enriched.
Associated endophenotype Canonical pathway Overlap molecules p
WAIS-R Digit symbol EIF2 signalling EIF5, RPL9, RPL14, RPS27 6.8× 10−5
Antigen presentation pathway HLA-G, PSMB8 7.2× 10−4
Neuroprotective role of THOP1 in Alzheimer's disease HLA-G, PRKAR2A 8.4× 10−4
Molecular mechanisms of cancer CDKN1B, DAXX, PRKAR2A 6.9× 10−3
Breast cancer regulation by stathmin1 CDKN1B, PRKAR2A 2.0× 10−2
Factor Verbal working memory Acyl carrier protein metabolism AASDHPPT 4.8× 10−4
Lysine degradation II AASDHPPT 2.4× 10−3
Lysine degradation V AASDHPPT 2.4× 10−4
DNA double-strand break repair by homologous recombination RAD50 6.8× 10−3
DNA double-strand break repair by non-homologous end joining RAD50 6.8× 10−4
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persons' general cognitive ability (McGrath et al., 2014; Mortensen
et al., 1999; Mortensen et al., 2010; Tuulio-Henriksson et al., 2003).
Overall, information processing speed is an important cognitive process
that is impaired in major psychiatric illness (Dickinson, 2008) and at
old age. In our study, WAIS-R Digit symbol test was measuring in-
formation processing speed. Previous studies have shown that genes
associated with information processing speed are related to the biolo-
gical functions; cell junction, focal adhesion, receptor binding, and
cellular metabolic process (Luciano et al., 2011). While another study
reported association between information processing speed and the
CADM2 gene, which encodes a protein involved in glutamate signalling
and is a candidate gene for Autism Spectrum Disorder, and personality
(Ibrahim-Verbaas et al., 2016).
Previous studies have shown gene expression changes related to
lithium treatment monotherapy in patients with bipolar disorder
(Anand et al., 2016) and for clozapine treatment monotherapy in pa-
tients with psychosis (Harrison et al., 2016). We explored 50 medica-
tions that belonged to 11 medication groups (typical antipsychotic,
atypical antipsychotic (excluding clozapine), clozapine, antidepressive,
anticholinergic, benzodiazepines, lithium, mood stabilizers, statin,
cardiovascular, and hypertensive) for possible effects on whole blood
gene expression levels. However, several individuals in our data were
on polypharmacy and had been taking the medications for years, it was
not possible to measure the effect of monotherapy in our data. In this
cohort, no medication group tested had a significant effect on gene
expression measures, and was therefore not included as a covariate in
our analyses conducted with the cognitive endophenotypes. However,
here diagnosis almost completely overlaps with antipsychotic medica-
tion reporting, and we needed to account for the effect of diagnosis on
both endophenotypes and gene expression by including it as a cov-
ariate. Thus we were unable to test the effect of antipsychotic medi-
cations in general, as their effect is likely entwined in this cohort with
that of diagnosis. We analysed the probes that showed tentative un-
corrected association (at the level of p < .01) with clozapine use, and
noticed that different genes were associated with clozapine use than
with our cognitive endophenotypes. Intriguingly, the canonical path-
ways in which the probes related to clozapine were enriched are related
to biological functions linked to peripheral immune cell disruption,
including abnormal morphology, lack of, and differentiation of lym-
phocytes. Clozapine use is known to have effects on peripheral immune
cells, and cause severe conditions including neutropenia, which is why
regular blood monitoring is required during treatment (Howes et al.,
2012).
The main limitation of the study is the small sample size and the
implied reduced power to detect changes in gene expression comes with
it. However, we have demonstrated that we have 80% power to detect
large changes in gene expression (here maximum effect size Δ=0.80),
which is for the observed 90th percentile of the standard deviation for
all genes from our data (SD σ=1.34) (Fig. S2). This power is reduced
in multivariate analysis with covariates. However, the sample used in
this study is relatively homogenous, as the study cohort is Finnish data
with individuals diagnosed with disorders along the schizophrenia
spectrum and their family members. With a less homogenous sample
the gene expression standard deviations would be larger and thus the
changes in probe expression levels would not be detectable with the
same sample size. Another limitation is validation of the results. This
study was designed to explore if whole blood gene expression changes
could be associated with cognitive performance, not to accurately de-
termine the fold-changes of these findings. Thus, we did not validate
our microarray results with RT-qPCR. Instead several other methods
were applied to keep the number of false positives low. As the smaller
reported p-value has shown to elevate the confidence in the accuracy of
the microarray results (Chuaqui et al., 2002), a stringent FDR of 5% was
applied for our analyses. We report all findings at this level, however,
these would not survive multiple test correction across the 19 tests
performed (Bonferroni Threshold q < 0.0026). Thus, we have focused
on those probes with supporting evidence from the analysis of these
related endophenotypes. Furthermore, the biological relevance of the
pathways in which the detected genes were enriched further support
our results (for enrichment analyses FDR 10% was used). A separate
healthy control group was not used in this study because the sample
included healthy family members.
Our observation that expression of immunological process related
genes vary with cognitive performance in familial schizophrenia further
supports the genomic discoveries made (Chan et al., 2017; Gardiner
et al., 2013; Schizophrenia Working Group of the Psychiatric Genomics,
2014; Schmitt et al., 2011; Wu et al., 2016; Xu et al., 2012), suggesting
that inflammatory responses are related to the pathophysiology and
development of schizophrenia. Thus immune or inflammatory processes
may be of biological interest for future drug design towards schizo-
phrenia and the cognitive dysfunctions that underlie it.
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